NCIC CLINICAL TRIALS GROUP

HEAD AND NECK

EATON CHELSEA HOTEL, TORONTO, ON
ROOM: WREN

SUNDAY MAY 3, 2014, 8:00 AM – 10:00 AM

CO-CHAIRS: J. WALDRON & L. SIU
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

− To understand and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
− To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
− To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research related to head and neck malignancies.

8:00 am Welcome.

8:05 am HN6 final analysis results. J. Waldron/L. Siu

8:30 am HN6 quality of life analysis. J. Ringash

Updates on previously discussed proposals

8:45 am Randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer. NRG-HN002 J. Waldron

Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA). J. Waldron

New Study Proposal

9:00 am Accelerated chemo-radiotherapy with/without nimorazole in HPV/p16-ve squamous cell head and neck cancer. EORTC 1219/DAHANCA-29 K. Sultanem

9:50 am Status of immune checkpoint inhibitors in head and neck cancer. L. Siu

9:55 am Other business.

10:00 am Meeting Adjourned.